Aluminium-related osteodystrophy and desferrioxamine treatment: role of phosphorus

Aluminium-related osteodystrophy and desferrioxamine treatment: role of phosphorus

We investigated (1) the prevalence of aluminium overload among 96 patients with symptomatic bone disease haemodialysed from 1987 to 1989 in the Sao Paulo area, Brazil; (2) the effect of 6 months desferrioxamine (DFO) treatment (1–2 g/week). All patients underwent a first bone biopsy. Aluminium overl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nephrology, dialysis, transplantation dialysis, transplantation, 1994, Vol.9 (6), p.668-674
Hauptverfasser: Jorgetti, V., Ricco Soeiro, N. M., Mendes, V., Pereira, R. C., Crivellari, M. E., Coutris, G., Borelli, A., Ribeiro Leite, M. O., Nussenzweig, I., Marcondes, M., Drüeke, T., Cournot, G.
Format: Artikel
Sprache:eng
Schlagworte:
aluminium
bone formation
bone mineralization
desferrioxamine
phosphorus
renal osteodystrophy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We investigated (1) the prevalence of aluminium overload among 96 patients with symptomatic bone disease haemodialysed from 1987 to 1989 in the Sao Paulo area, Brazil; (2) the effect of 6 months desferrioxamine (DFO) treatment (1–2 g/week). All patients underwent a first bone biopsy. Aluminium overload (extent of stainable bone aluminium more than 20% trabecular surface) was observed in 74 of 96 patients. Forty overloaded patients were divided into patients with high bone formation rate (BFR) (group 1; n=17) and patients with low BFR (group 2; n=23), and had a second biopsy after DFO therapy. In both groups aluminium surface was reduced after treatment (P
ISSN:0931-0509
1460-2385
DOI:10.1093/oxfordjournals.ndt.a092948